JP2009519949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519949A5 JP2009519949A5 JP2008545850A JP2008545850A JP2009519949A5 JP 2009519949 A5 JP2009519949 A5 JP 2009519949A5 JP 2008545850 A JP2008545850 A JP 2008545850A JP 2008545850 A JP2008545850 A JP 2008545850A JP 2009519949 A5 JP2009519949 A5 JP 2009519949A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- des
- peptide
- octapeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75141205P | 2005-12-16 | 2005-12-16 | |
| PCT/US2006/047953 WO2007075439A2 (en) | 2005-12-16 | 2006-12-15 | Compositions and methods for treating obesity and related metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009519949A JP2009519949A (ja) | 2009-05-21 |
| JP2009519949A5 true JP2009519949A5 (enExample) | 2010-01-21 |
Family
ID=38218466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008545850A Pending JP2009519949A (ja) | 2005-12-16 | 2006-12-15 | 肥満症および関連する代謝性疾患の治療のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090209460A1 (enExample) |
| EP (1) | EP1973953A2 (enExample) |
| JP (1) | JP2009519949A (enExample) |
| AU (1) | AU2006329836A1 (enExample) |
| CA (1) | CA2634016A1 (enExample) |
| WO (1) | WO2007075439A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| KR101106510B1 (ko) | 2006-05-30 | 2012-01-20 | 인타르시아 세라퓨틱스 인코포레이티드 | 투피스, 내부채널 삼투압 전달 시스템 유동 조절기 |
| CA2670821C (en) | 2006-08-09 | 2012-05-15 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
| WO2008097536A2 (en) | 2007-02-05 | 2008-08-14 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating psychiatric diseases and disorders |
| CA2683610C (en) | 2007-04-23 | 2013-01-08 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
| WO2009040020A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Amylin as a therapeutic agent |
| US20100184698A1 (en) * | 2007-09-11 | 2010-07-22 | Dorian Bevec | Use of a deslorelin and mastoparan as a therapeutic agent |
| WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| CN102459311B (zh) * | 2009-04-08 | 2015-08-19 | 武田药品工业株式会社 | 神经调节肽u衍生物 |
| PL2427475T3 (pl) * | 2009-05-08 | 2021-07-19 | Techfields Biochem Co., Ltd. | Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami |
| MX378797B (es) | 2009-09-28 | 2025-03-10 | Intarcia Therapeutics Inc | Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco. |
| JP2013209295A (ja) | 2010-10-13 | 2013-10-10 | Takeda Chem Ind Ltd | ペプチド誘導体 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| CN113598842A (zh) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | 植入物放置和移除系统 |
| KR102574993B1 (ko) | 2016-05-16 | 2023-09-06 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| WO2018129058A1 (en) | 2017-01-03 | 2018-07-12 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug |
| WO2018175924A1 (en) | 2017-03-24 | 2018-09-27 | The Broad Institute, Inc. | Methods and compositions for regulating innate lymphoid cell inflammatory responses |
| US20240279278A1 (en) | 2023-01-12 | 2024-08-22 | Boehringer Ingelheim International Gmbh | Nmu receptor 2 agonists |
| WO2026013210A1 (en) | 2024-07-11 | 2026-01-15 | Boehringer Ingelheim International Gmbh | Novel nmu receptor 2 agonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001081418A1 (en) * | 2000-04-27 | 2001-11-01 | Merck & Co., Inc. | New neuromedin u receptor nmur2 and nucleotides encoding it |
| JP2002265497A (ja) * | 2001-03-12 | 2002-09-18 | Tadashi Hashimoto | 生理活性ペプチドニューロメジンｕの高活性誘導体 |
| US8076288B2 (en) * | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| CA2592201C (en) * | 2004-12-24 | 2016-08-09 | Japan As Represented By The President Of National Cardiovascular Center | Neuromedin s and the use thereof |
| AU2006279680B2 (en) * | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
| WO2008097536A2 (en) * | 2007-02-05 | 2008-08-14 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating psychiatric diseases and disorders |
-
2006
- 2006-12-15 JP JP2008545850A patent/JP2009519949A/ja active Pending
- 2006-12-15 AU AU2006329836A patent/AU2006329836A1/en not_active Abandoned
- 2006-12-15 WO PCT/US2006/047953 patent/WO2007075439A2/en not_active Ceased
- 2006-12-15 US US12/097,737 patent/US20090209460A1/en not_active Abandoned
- 2006-12-15 CA CA002634016A patent/CA2634016A1/en not_active Abandoned
- 2006-12-15 EP EP06845564A patent/EP1973953A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020201322B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| ES2976562T3 (es) | Derivado del glucagón | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2006515351A5 (enExample) | ||
| BR112013032375B1 (pt) | Conjugado, composição farmacêutica e uso dos mesmos | |
| US12018060B2 (en) | Glucagon derivatives | |
| TW201202265A (en) | Glucagon analogues | |
| RU2012136530A (ru) | Новые соединения, влияющие на пищевое поведение | |
| US20090209460A1 (en) | Compositions and methods for treating obesity and related metabolic disorders | |
| BR112020003319A2 (pt) | análogo de peptídeo de oxintomodulina acilada | |
| KR20260025094A (ko) | 개선된 특성을 가진 유사체 | |
| WO2024261076A1 (en) | Weight loss | |
| HK40010066B (en) | Glucagon derivative | |
| NZ727090A (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| HK1192261B (zh) | 新型泌酸调节肽衍生物和包含该泌酸调节肽衍生物的用於治疗肥胖的药物组合物 | |
| NZ731342B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| BR112017014205B1 (pt) | Derivados de glucagon e seu uso, e uso de uma composição farmacêutica | |
| NZ717174B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| NZ740049B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| NZ734808B2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |